Fig. 2From: Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitroTF protein reduction in A-375 cells treated for 48 h with the combination Dabrafenib and Trametinib compared to DMSO as control. The istograms describe the reduction by Western blot analysis (a), confirmed by immunocytochemistry (b)Back to article page